How Mark Cuban's Cost Plus Drugs is Transforming the Pharma Industry [The DaVinci Hour Podcast Ep26]

Описание к видео How Mark Cuban's Cost Plus Drugs is Transforming the Pharma Industry [The DaVinci Hour Podcast Ep26]

In this episode Dr. Maxwell Cooper interviews Mark Cuban, a serial entrepreneur, Owner of the Dallas Mavericks NBA Team, a Shark on ABC's Shark Tank Series, and Co-Founder of Mark Cuban Cost Plus Drugs. Mark outlines how Cost Plus Drugs is obtaining medications directly from manufacturers and wholesalers to provide medications at the lowest prices possible in the most transparent way. He also describes how physicians can easily send prescriptions to CostPlusDrugs.com and how patients can sign up. Mark tells the story of how his Co-Founder, Dr. Alex Oshmyansky cold emailed him about starting Cost Plus Drugs. Lastly, Mark describes his experience working with physician-entrepreneurs and gives advice for physicians starting companies.

*Views expressed in this podcast are those of the individuals, not their respective institutions

All Episodes of The DaVinci Hour Podcast:    • Плейлист  
More DaVinci Innovators Episodes:    • Interview with Amy Baxter, MD, Founde...  
Podcast Website: https://www.dviacademy.com/the-davinc...

Mark Cuban Cost Plus Drugs
Website: https://costplusdrugs.com/
Twitter:   / costplusdrugs  
Instagram:   / costplusdrugs  
LinkedIn:   / costplusdrugs  

Audio for this episode available on:
Podcast Website: https://www.dviacademy.com/the-davinc...
Spotify: https://open.spotify.com/episode/73Bq...
Apple Podcasts: https://podcasts.apple.com/us/podcast...
Google Podcasts: https://podcasts.google.com/feed/aHR0...

20% off Discount Code (TDH20) for our online video courses and books available at https://www.dviacademy.com/store

DaVinci Academy
Website: https://www.dviacademy.com/
Twitter:   / dviacademy  
Instagram:   / davinci_academy1  
Facebook:   / dviacademy  
LinkedIn:   / davinci-academy---dviacademy.com  

#markcuban #costplusdrugs #drugprices #pharmacy #pharmaceuticals

Комментарии

Информация по комментариям в разработке